Insights and examples of how collaborative efforts can lead to the development of innovative therapies that target unmet patient needs.
A proactive and tailored compliance department—with the nimbleness to adapt strategies on the fly—is a critical shield for life sciences companies during government investigations.
Providing ultimate value to stakeholders remains key in new style of development.
U.S. patent law will have to adapt to the use of AI in the life sciences industry.
As regulatory reform continues to evolve in the US and Europe, the role of regulatory affairs is poised to help shape the more personalized treatment landscape on the horizon.
NJ can regain leadership in pharma by offering modern lab spaces for biotech and other lab-based growth companies.
Analytics capabilities are no longer a nice-to-have, but a necessity to build and maintain a successful business and competitive edge.
Amy West, Head of US Digital Health & Innovation Strategy at Novo Nordisk, shares her insights on fostering collaboration, embracing change, and her compelling vision to revolutionize digital transformation and innovation in the field of healthcare.
Stay-at-home orders during the pandemic forced a shift in patient preferences—and the pharma industry has responded.
Addressing the challenges created by virtual meetings with HCPs, what we have learned about virtual meetings so far, and a look into the future.
Life sciences professionals will need to keep up with market demand for biologics and biosimilars.
How a large, global biopharma company is leveraging a data-linking strategy to power insight-generation tools and techniques—and supporting customers through their journey with dynamic personalization and modular content.
Webinar Date/Time: Tue, Nov 19, 2024 11:00 AM EST
Learnings from a roundtable discussion with Medical Affairs leadership from 11 pharma companies
By using correct data and pertinent ML algorithms, customer engagement leaders can identify deep insights into customer behavior and make the right interventions to transform the customer experience.
How effective training programs enable ‘next-generation’ patient engagement.
Healthcare professionals (HCPs) shouldn’t miss out on critical information while their focus is on their patients, which is why messages on professional platforms are an essential resource to improve a patient’s health results, writes Gareth Shaw.
Clinical studies are increasingly designed to satisfy evidentiary needs.
The diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.
Presenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.
Outlining four considerations for biopharma companies in ensuring that their approach to replacing and filling key leadership positions is more truly aligned with future goals in business delivery and risk management.
The importance of pre-approval information exchange (PIE) with payers and other strategic considerations to help navigate today’s market access challenges and regulatory requirements in bringing promising cell and gene therapies to the market.
Mitigating potential risk for stakeholders in light of latest Sunshine Act developments.
Marketers are working to reimagine how they leverage key opinion leader (KOL) support during COVID-19.
Healthcare customers and patients are facing more avenues to receive misinformation about drugs than ever before.
Are you working with a network or a committee?